BETA Technologies launches IPO of 25 million shares priced $27-$33
Director Klein Joseph III of Ionis Pharmaceuticals Inc (NASDAQ:IONS) sold 28,000 shares of common stock on September 3, 2025, at a price of $60.0, totaling $1,680,000. The transaction comes as the stock trades near its 52-week high of $62.08, having gained over 75% in the past six months. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
The sale was executed under a Rule 10b5-1 trading plan adopted on January 3, 2024. On the same day, Klein also exercised options to acquire 12,000 shares and 16,000 shares of Ionis Pharmaceuticals stock at exercise prices of $42.88 and $52.22, respectively. These option exercises were related to non-qualified stock options and the transactions totaled $0. With a market capitalization of $9.47 billion, Ionis represents a significant player in the pharmaceutical sector.
Following these transactions, Klein directly holds 16,346 shares and indirectly holds 100 shares through his son. For deeper insights into IONS’s insider trading patterns and comprehensive financial analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Ionis Pharmaceuticals has reported significant developments that have caught the attention of investors and analysts alike. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, showing statistically significant benefits in triglyceride lowering and reducing the risk of acute pancreatitis. Following these results, RBC Capital raised its price target for Ionis to $80, citing the promising data from the trials. Similarly, H.C. Wainwright increased its price target to $95, maintaining a Buy rating, due to the strong triglyceride reductions observed in the studies.
BMO Capital also upgraded Ionis Pharmaceuticals from Market Perform to Outperform, highlighting the blockbuster potential of Olezarsen, which exceeded both analyst and investor expectations. Oppenheimer joined the trend by raising its price target to $81, maintaining an Outperform rating, after the announcement of successful Phase 3 trial results for Tryngolza (olezarsen) in treating severe hypertriglyceridemia. These developments reflect a growing confidence in Ionis Pharmaceuticals’ pipeline, as evidenced by the positive reception from several prominent analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.